Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
BMO$175.88+2.05(+1.18%)Stonepeak Completes Acquisition of BMO's Transportation and Vendor Finance Businesses and Launches Longview Capital Solutions[6:39:00 PM ET]TCBS$17.28+0.18(+1.05%)TEXAS COMMUNITY BANCSHARES, INC. AND THE BANC OF SAN JACINTO COUNTY BANCSHARES, INC., THE PARENT OF THE BANK OF SAN JACINTO COUNTY, COLDSPRING, TEXAS, ANNOUNCE MERGER AGREEMENT Texas Community Bancshares, Inc. (NASDAQ: TCBS) (the "Company") and The Banc of San Jacinto County Bancshares, Inc. ("SJCB") jointly announced today...[6:39:00 PM ET]BDIMF$14.03+0.28(+2.03%)Black Diamond Reports Strong Third Quarter Results with Record Consolidated Revenue and Increases Dividend by 22%[6:32:38 PM ET]WPRT$2.220.00(0.00%)Aetherion to Issue Q3 2026 Financial Results on November 12, 2026[6:30:00 PM ET]LSF$2.67-0.02(-0.74%)Laird Superfood to Report Third Quarter 2026 Financial Results on November 12, 2026[6:30:00 PM ET]BMO$175.88+2.05(+1.18%)BMO Closes Sale of Transportation and Vendor Finance Businesses BMO Financial Group (TSX: BMO) (NYSE: BMO) today announced it has closed the previously announced sale of its Transportation Finance and Vendor...[6:30:00 PM ET]LEGH$28.93+0.53(+1.87%)Legacy Housing Corporation Announces Timing of Third Quarter 2026 Earnings Release and Conference Call[6:18:08 PM ET]BFST$32.27+0.63(+1.99%)Business First Bancshares, Inc. Announces Stock Repurchase Program[6:15:00 PM ET]ONGRF$0.37-0.00(-1.22%)ONGold Files NI 43-101 Technical Report for the Monument Bay Gold Project, Manitoba[6:07:00 PM ET]GTE$11.31-0.26(-2.25%)Gran Tierra Energy Inc. Provides Release Date for its 2026 Third Quarter Results[6:05:00 PM ET]PSA$317.46+7.41(+2.39%)Public Storage Prices Public Offering of $500 Million of Senior Notes at an Effective Interest Rate of 5.200%[5:57:00 PM ET]KCLI$34.74+0.09(+0.25%)Kansas City Life Announces Appointment of Kellie S. Needham as Director Kansas City Life Insurance Company (the "Company") announces that the Board of Directors has appointed Kellie S. Needham to the Board effective...[5:56:00 PM ET]

LENZ · NASDAQ

LENZ Therapeutics, Inc.

$3.43 +0.24 (+7.69%)

Company overview

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101, which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$108M
Employees
6
Headquarters
Solana Beach, CA
Website
lenz-tx.com
CEO
Evert Schimmelpennink
Listed
March 22, 2024
P/E
-0.95
Dividend yield
89.01%

Company financials

Revenue
$21M
Gross profit
$19.1M
Operating income
-$118M
EBITDA
-$118M
Net income
-$109M
EPS
-$3.60
Total assets
$273M
Total debt
$237,000
Gross margin
91.16%
Net margin
-519.30%
Earnings yield
-104.96%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

2.764.796.828.8510.88
LENZ 1D NASDAQ O3.10H3.22L3.07C3.21+0.06 (+1.90%)Vol573.90K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics, Inc. (LENZ) Q3 2026 Earnings Call Transcript Seeking Alpha
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics Q3 Earnings Call Highlights MarketBeat
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates Zacks Investment Research
LENZLENZ Therapeutics, Inc. Press release LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession GlobeNewswire
LENZLENZ Therapeutics, Inc. Press release LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 GlobeNewswire
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics: Still Speculative But Priced For Disasters Seeking Alpha
LENZLENZ Therapeutics, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ GlobeNewsWire
LENZLENZ Therapeutics, Inc. Stock news Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. $LENZ Defense World
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript Seeking Alpha
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics Q2 Earnings Call Highlights MarketBeat
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates Zacks Investment Research
LENZLENZ Therapeutics, Inc. Press release LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights GlobeNewsWire
LENZLENZ Therapeutics, Inc. Press release LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 GlobeNewsWire
LENZLENZ Therapeutics, Inc. Stock news Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline Zacks Investment Research
LENZLENZ Therapeutics, Inc. Press release LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia GlobeNewsWire
LENZLENZ Therapeutics, Inc. Stock news Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing Fool - Investing News
LENZLENZ Therapeutics, Inc. Press release LENZ Therapeutics to Participate in Upcoming Investor Conferences GlobeNewsWire
LENZLENZ Therapeutics, Inc. Stock news Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More 247 Wallst
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript Seeking Alpha
LENZLENZ Therapeutics, Inc. Stock news LENZ Therapeutics Q1 Earnings Call Highlights MarketBeat
See more
FAQ

Questions about LENZ Therapeutics, Inc.

What does LENZ Therapeutics, Inc. do?
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101, which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
What is LENZ's market cap?
LENZ Therapeutics, Inc. (LENZ) is a listed stock with a live quote. The latest market cap on this page is $108M.
Where is LENZ Therapeutics, Inc. headquartered?
LENZ Therapeutics, Inc. is headquartered in Solana Beach, CA.
How do I get LENZ news from the API?
Call GET /v1/news?tickers=LENZ. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does LENZ news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for LENZ, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the LENZ price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs